腹腔镜肝切除用于临床显著门脉高压的肝细胞癌:倾向性评分匹配研究
匹配后两组手术时间、出血量、输血率、中转开腹率、切缘、手术死亡率及综合并发症指数均无差异,CSPH组术后住院时间有延长趋势(p=0.054)。3年总生存率CSPH组62.9% vs 非CSPH组84.3%(p=0.1090),匹配后结果相似(p=0.5734)。结论认为腹腔镜肝切除对合并门脉高压的肝细胞癌安全可行。
要点
- 腹腔镜肝切除可用于合并临床显著门脉高压的肝细胞癌患者。
- 匹配后CSPH组仅术后住院时间有延长趋势(p=0.054),其余手术结局无差异。
- 3年总生存率两组差异无统计学意义(p=0.1090),匹配后相似(p=0.5734)。
核心结论
- 腹腔镜肝切除对合并门脉高压的肝细胞癌患者安全可行,微创手术可适当扩大肝切除适应证。
研究设计与样本
- 单医疗团队回顾性队列研究,纳入2016年2月至2019年9月行腹腔镜肝切除患者156例,CSPH组26例、非CSPH组130例,并行倾向性评分匹配。
主要发现
- CSPH组临床肝功能障碍体征更多(p<0.05)。
- 匹配后(n=48)CSPH组术后住院时间有延长趋势(p=0.054)。
- 匹配后两组手术时间(p=0.329)、出血量(p=0.392)、输血率(p=0.701)、中转开腹率(p=0.666)、切缘(p=0.306)、手术死亡率(n=0)及综合并发症指数(p=0.844)均无差异。
- 全队列中位随访19.6个月(范围0.2-40.6个月),3年总生存率CSPH组62.9%、非CSPH组84.3%(p=0.1090),匹配后相似(p=0.5734)。
临床怎么用
- 对合并临床显著门脉高压的肝细胞癌患者,腹腔镜肝切除可作为可选术式,但需关注术后住院时间可能延长。
局限性
- 单医疗团队回顾性研究,CSPH组样本量较小(26例),随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The presence of clinically significant portal hypertension (CSPH) remains a relative contraindication to liver resection for patients with resectable hepatocellular carcinoma (HCC). The goal of this study was to explore whether a laparoscopic approach could extend the indications for hepatectomy to patients with PH. METHOD: Patients who underwent laparoscopic liver resection (LLR) from February 2016 to September 2019 performed by a single medical team were included in this study. We analyzed the surgical and oncological outcomes between groups with and without CSPH before and after propensity score matching (PSM). RESULT: We enrolled 156 patients divided into two groups according to the presence (CSPH, n = 26) or absence (non-CSPH, n = 130) of CSPH. CSPH group was associated with more clinical signs of liver dysfunction (p < 0.05). After PSM (n = 48 patients), the CSPH group tended to have a longer postoperative hospital stay (p = 0.054); however, there was no difference in operation time (p = 0.329), blood loss volume (p = 0.392), transfusion rates (p = 0.701), rate of conversion to open surgery (p = 0.666), surgical margin (p = 0.306), surgical mortality (n = 0), or comprehensive complication index (p = 0.844) between the two groups. The median follow-up time for the entire cohort was 19.6 months (range 0.2-40.6 months). The 3-year overall survival rate was 62.9% in the CSPH group and 84.3% in the non-CSPH group (p = 0.1090), and results were similar after PSM (p = 0.5734). CONCLUSIONS: LLR is safe and feasible for HCC with PH. The introduction of minimally invasive surgery, represented by LLR, can appropriately expand the indications for hepatectomy.
引用
- Zheng J, Feng X, Liang Y, et al. Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study. Surg Endosc. 2020. PMID: 32632488. doi:10.1007/s00464-020-07763-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。